JPRN-C000000117CompletedPhase 3
Phase 3 study of docetaxel vs vinorelbine in elderly patients with advanced non-small cell lung cancer - Phase 3 study of docetaxel vs vinorelbine in elderly patients with advanced non-small cell lung cancer
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- West Japan Oncology Group
- Enrollment
- 180
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 70years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with symptomatic brain metastasis or apparent dementia were ineligible. Patients with active concomitant malignancy, massive pleural effusion or asites, active infection, severe heart disease, grade 2 or higher ECG abnormality, uncontrolled diabetes mellitus, ileus, pulmonary fibrosis, diarrhea, and a bleeding tendency were excluded.
Investigators
Similar Trials
Completed
Phase 3
Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung CancerLung CancerNCT00148291West Japan Thoracic Oncology Group180
Completed
Not Applicable
Comparison of vinorelbine versus docetaxel, and trastuzumab versus no trastuzumab as adjuvant treatments of early breast cancerBreastBreast cancerCancerISRCTN76560285Finnish Breast Cancer Group, HYKS Institute1,010
Unknown
Phase 2
Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast CaBreast CancerNCT02144194Cancer Research Group - Collaborative Group, Beirut, Lebanon.65
Completed
Phase 3
Phase3 study of docetaxel/TS-1 versus docetaxel in patients with previously treated non-small cell lung canceron-small cell lung cancer patients with postoperative recurrence or stage3-4 with chemotherapy treatment historyJPRN-UMIN000011391Kanto respiratory disease study group260
Recruiting
Phase 3
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)10038597prostate cancerNL-OMON54758Memorial Sloan Kettering Cancer Center250